Background: To support translational lung MRI research with hyperpolarized
compared to 129 Xe. However, recent years have seen an increase in 129 Xe lung MRI 1 studies in patients for assessment of lung ventilation, 2-5 microstructure, 6, 7 and regional gas exchange 8 with this naturally abundant isotope. This renewed interest is attributable to the relative scarcity of 3 He gas, 9 and parallel developments in 129 Xe gas polarization technology [10] [11] [12] [13] and MRI pulse sequences 14 that have helped bridge the gap in image quality due to the difference in gyromagnetic ratio between the two nuclei. Previous comparisons of the sensitivity of 3 He and 129 Xe MRI for assessment of lung ventilation and microstructure have been reported in healthy subjects, former smokers, 7 patients with chronic obstructive pulmonary disease (COPD), 3, 15 and asthma. 16 Generally, lung ventilation and microstructural information of similar diagnostic quality has been obtained with the two nuclei, despite their different diffusivity in the lung airspaces. However, all of these reported studies were carried out at 3T, at relatively modest spatial resolution (15 mm and 30 mm slice thickness for ventilation and diffusion-weighted microstructural MRI, respectively), and at a single site. 3, 7, 15, 16 Magnetic susceptibility differences at 1.5T and 3T have been shown to have some impact on lung ventilation and diffusion-weighted microstructural MRI with both gases 17, 18 ; however, quantitative information derived from 3 
He and
129 Xe techniques at the most-reported field strength to date for lung MRI (1.5T) has yet to be systematically compared. This information is critical for multisite implementation and widespread clinical dissemination of 129 Xe MRI in the future. In addition, future clinical use of 129 Xe will require quantitative data regarding the repeatability and robustness of associated MRI biomarkers of lung disease. The most commonly reported quantitative metrics of lung ventilation from conventional, static hyperpolarized gas images are percentage ventilated volume (VV%) and ventilation defect percentage (VDP 5 100% -VV%). Same-day 3 He VDP measurements were reported to be highly repeatable at 3T in patients with COPD, 19 ,20 while 1-week repeatability was relatively poorer. Good same-day and same-week repeatability of 3 He VV% has been reported in cystic fibrosis (CF) patients at 1.5T 21 and 3T, 22 respectively. One report of high same-session repeatability of 129 Xe VDP in healthy subjects and asthma patients has been published recently 23 ;
however, multisession, multiday variability in quantitative lung ventilation metrics derived from 129 Xe MRI has not been assessed. Delivery of several doses of 129 Xe gas for ventilation imaging on the same/subsequent day to subjects with a variety of pulmonary conditions has been reported. 2, 24 However, the primary purpose of those studies was to assess safety and tolerability, and ventilation volume repeatability was not evaluated. The global mean 3 He apparent diffusion coefficient (ADC) in the lung airspaces derived from diffusionweighted MRI is a well-established marker of alveolar microstructural change. Comprehensive investigations of same-session 25 and multiday 26 repeatability of mean 3 He ADC values have demonstrated a high intra-individual repeatability in healthy subjects and patients with emphysema. Furthermore, studies at 3T have highlighted a higher repeatability of 3 He ADC when compared to 3 He VDP in patients with COPD. 19, 20 However, to our knowledge, interscan repeatability of 129 Xe ADC has not been assessed to date. Evaluation of the repeatability of lung ventilation and microstructural metrics derived from 129 Xe MRI against 3 He MRI and pulmonary functional tests is therefore necessary to facilitate the clinical dissemination of these methods.
Taking the gaps in the literature discussed above into account, the purpose of this work was to evaluate the applicability and repeatability of quantitative metrics of 129 Xe ventilation and diffusion-weighted MRI as compared to the equivalent 3 He measurements made at a field strength of 1.5T.
Materials and Methods

Subjects
We present an analysis of MR data obtained from several distinct studies. Two groups of healthy nonsmokers: a) 11 participants (age 5 43 6 6 years), and b) three participants (age 5 31 6 4 years), all with no history of smoking or respiratory disorders; five ex-smokers with a pack history of 10 years and no history of respiratory disorders (age 5 51 6 2 years); five patients with COPD (GOLD stage: 3D [n 5 4], 3B [n 5 1]; age 5 67 6 7 years); and 16 patients with nonsmall-cell lung cancer (NSCLC) (age 5 67 6 12 years) were recruited for separate studies approved by the National Research Ethics Committee, with governance approval from the local National Health Service research committee. All subjects provided written informed consent. Patient demographics and pulmonary function test (PFT) results are summarized in Table 1 . Subjects with a resting oxygen saturation of <90%, unstable cardiac disease, or (for NSCLC patients) comorbid conditions that precluded radiotherapy, were excluded.
MRI Technique
All subjects underwent MRI at 1.5T (GE HDx, GE Healthcare, Milwaukee, WI). Flexible quadrature radiofrequency coils were employed for transmission and reception of MR signals at the Larmor frequencies of 3 He and 129 Xe (Clinical MR Solutions, Brookfield, WI). 3 He and 129 Xe gas was polarized by collisional spinexchange optical pumping, using a prototype commercial 3 He polarizer (MITI, Durham, NC) (average polarization 25%) and a home-built 129 Xe polarizer 12, 27 (average polarization 10-15%),
respectively.
Patients with NSCLC and COPD, and three healthy nonsmokers (group b) underwent 3D lung ventilation MRI with a steady-state free precession (SSFP) sequence at breath-hold after inhalation of 3 He or 129 Xe gas. 14,28 1 H images of the thorax were also acquired for anatomical reference and calculation of total lung volume. As illustrated in Fig. 1 3 He images is half that of 129 Xe images; see Table 2 ). Right: Corresponding breath-hold scheme for ventilation imaging scans. Scans were acquired in the order shown, with a change of RF coil and repositioning of the patient between 3 He and 129 Xe scans. He isotope, 0.75% N 2 ) or 129-enriched xenon (86% 129 Xe) gas was balanced to 1 L with N 2 in a Tedlar bag and inhaled via a sterilized air filter. Prior to image acquisition, subjects inhaled from functional residual capacity (FRC) after a period of steady breathing. Target inhaled gas doses were achieved to within a tolerance of 6 10 mL for 3 He and 6 20 mL for 129 Xe. Images with a signal-to-noise ratio (SNR) of <5
were not included in quantitative analysis. This threshold was determined by quantitative evaluation of the effect of SNR on ventilation heterogeneity 30 by incrementally adding noise to high SNR ventilation images. Healthy nonsmokers (group a), ex-smokers, and COPD patients underwent 2D multislice 3 He and 129 Xe diffusionweighted lung MRI to acquire ADC maps of the lungs. ADC values were calculated from the first two interleaves of a multiple bvalue 2D diffusion-weighted spoiled gradient echo sequence. Acquisition parameters and bipolar diffusion gradient timing parameters are summarized in Table 2 . Gradients were designed to achieve comparable diffusion weighting for the two nuclei, and slice locations were matched (with an additional anterior slice for 3 He acquisitions). The same SNR threshold as ventilation imaging was applied to diffusion-weighted MRI data. Note: Healthy nonsmokers (group a) and ex-smokers did not undergo ventilation imaging in this study. Likewise, patients with NSCLC and healthy group b did not undergo diffusion-weighted MRI.
Patients with COPD underwent the complete MR protocol on four separate scan sessions in total: twice on day 1; once on day 2; and once 2 weeks after day 1, to assess the repeatability of 3 He and 129 Xe metrics.
Pulmonary Function Testing
PFTs, including the diffusing capacity of the lung for carbon monoxide (D LCO ) and spirometry, were performed by each COPD patient, once on the same day as each MR session (three times in total, always following MRI). Healthy nonsmokers and ex-smokers performed the same tests immediately after their single-timepoint diffusion-weighted MR scans, and NSCLC patients performed PFTs within 61 week of MRI.
Statistical Analysis
VV% and global mean ADC (ADC glob ) values derived from 3 He and 129 Xe MRI were compared for differences in each metric Journal of Magnetic Resonance Imaging between two, or more than two, subject groups with conventional ttests or analyses of variance (ANOVA), respectively. Differences in metrics derived between gas nuclei were analyzed using Wilcoxon signed rank tests. Spearman's rank correlation coefficients were derived to quantify the relationship between 3 He and 129 Xe datasets, and Bland-Altman analysis was used to visualize systematic differences in VV% between the two nuclei. MRI metrics were compared and correlated against PFT results by calculating Spearman's rank coefficients. The mean of repeated measurements from each COPD patient was used to represent a single datapoint for the above statistical tests.
Where repeatability data were available, the coefficient of variation (CV) of each parameter was calculated as the ratio of the standard deviation (SD) to the mean over all repeated measurements, expressed as a percentage. In addition, two-way mixed intraclass correlation (ICC) coefficients were calculated for absolute agreement between repeat measurements. Statistical analyses were performed using IBM SPSS Statistics (v. 23, Armonk, NY) and R (R3.4, R Foundation for Statistical Computing, Vienna, Austria), and statistical significance level was set to P < 0.05.
Results
Imaging Data Quality
From the healthy nonsmokers cohort,
129
Xe diffusionweighted MR images from one subject exhibited insufficient SNR for accurate calculation of ADC maps. From the COPD cohort, one 3 He and one 129 Xe ADC dataset, and two 3 He and two
Xe VV% datasets (each out of a total of 20 datasets for each nucleus, each metric) were either not successfully acquired or image SNR was unsatisfactory. From the NSCLC patient cohort, one 3 He dataset and one 1 H dataset was not acquired successfully, and two 129 Xe datasets showed low SNR.
All other recorded data were of sufficient SNR for analysis: ie, for 3 He, >95% of ADC data and >90% of VV% data were acceptable; for 129 Xe, 95% of ADC data and >85% of VV% data were acceptable. All gas doses were well-tolerated and no significant side effects or adverse events were reported. Mean MR parameters and PFT results are shown in Table 1 .
Ventilation Imaging Representative 3
He and
129
Xe coronal ventilation images and corresponding structural 1 H images from patients with NSCLC and COPD are shown in Fig. 1 (left) , alongside images from a healthy nonsmoker. Considerable ventilation abnormalities were observed in patients with NSCLC, with most patients exhibiting a heterogeneous distribution of ventilated airspaces and complete absences of ventilation in the region of the lung associated with malignancies (as identified on structural 1 H MRI). Severe ventilation defects were detected in most COPD patients, and entire lobes of the lungs were often observed to be completely unventilated.
By pooling data from healthy nonsmokers (group b) and patients with NSCLC and COPD, a significant positive correlation between 3 He and 129 Xe VV%, was identified (Spearman's correlation coefficient, r 5 0.860, P < 0.001).
Derived VV% values were larger on average for 3 He when compared with 129 Xe (mean over all healthy group b, NSCLC, and COPD subjects); P < 0.001 (Wilcoxon signed rank) and qualitatively, typically larger and more numerous ventilation defects could be observed in 129 Xe images. A Bland-Altman plot of the systematic differences between 3 He and 129 Xe VV% is shown in Fig. 2 , indicating a bias of 18.79% towards higher 3 He VV%. Analyzing data from COPD and NSCLC patients separately, intragroup correlations between 3 He and 129 Xe VV% were statistically significant for NSCLC patients (r 5 0.657, P 5 0.024) but not COPD patients (r 5 0.700, P 5 0.233). Additionally, 3 He VV% values were found to be higher than 129 Xe VV% values when COPD (P 5 0.063, close to significant) and NSCLC (P 5 0.002, significant) patient data were analyzed separately. There were no significant differences in either mean 3 He VV% (P 5 0.095) or mean 129 Xe VV% (P 5 0.085) values between the two patient groups, although the VV% trended to be lower in COPD patients compared with NSCLC patients.
Diffusion-Weighted Imaging
Examples of 3 He and
129
Xe ADC maps obtained from a healthy nonsmoker and a patient with COPD are shown in Fig. 3 . ADC glob values of both nuclei were significantly elevated in COPD patients when compared to both healthy nonsmokers (group a) and ex-smokers: 3 He ADC glob 5 0. 432 Xe data, respectively. A strong positive correlation between 3 He and 129 Xe ADC glob was found when pooling data from healthy nonsmokers group a, ex-smokers and COPD patients together (Fig. 4 : Spearman's r 5 0.922, P < 0.001). Analyzing the three subject groups separately, significant correlations between 3 He and 129 Xe ADC glob were observed for each of the three groups (P < 0.05).
MR Metrics vs. PFTs
A summary of the statistical analyses of relationships between MR metrics and PFTs is presented in Table 3 . Both 3 He and 129 Xe VV% exhibited significant correlations with FEV 1 and FEV 1 /FVC at P < 0.001 (except 129 Xe VV% vs. FEV 1 , P < 0.05 significance level). Correlations of VV% values derived from both nuclei with D LCO were relatively weaker, although still significant at the P < 0.05 level. Note: One significant outlying datapoint from a patient with NSCLC with %-predicted spirometry 90% but low VV% values, 50% for both nuclei, was excluded from the analysis presented in Table 3 . When these outlying data were included in the analysis, the correlation statistics were severely affected; correlations of VV% with D LCO were no longer significant (P > 0.05) and all other correlations were significant at the P < 0.05 level, rather than P < 0.001 (Table 3 caption) .
ADC glob values also showed strong correlations with PFTs; notably, correlations of 3 He ADC glob with both FEV 1 and FEV 1 /FVC were significant at the P < 0.001 level, while correlations with D LCO were significant at the P < 0.05 level (Table 3) . Similarly, correlations of 129 Xe ADC glob with FEV 1 were significant to P < 0.001, and correlations with FEV 1 /FVC and D LCO were significant to P < 0.05.
Repeatability
In COPD patients, both 3 He and 129 Xe ventilation images appeared qualitatively similar (in terms of visual ventilation defect prevalence and ventilation homogeneity) at each of the four scan timepoints, as shown for a representative example in Fig. 5 . Mean CV values of 3 He and
129
Xe VV% between all repeated scans were 4.08% and 13.01%, respectively (Table 4) . According to ICC analysis, both 3 He VV% (ICC coefficient 0.541, P 5 0.061) and 129 Xe VV% (coefficient 0.458, P 5 0.095) repeatability-calculated by considering data from all scan timepoints-was classified as just beyond the 95% confidence level. The CV of 3 He VV% was comparable to that of PFTs, while the 129 Xe VV% CV was higher. Good agreement in the appearance of both 3 He and 129 Xe ADC maps was observed for each scan timepoint, as illustrated in Fig. 6 . Xe, respectively) significant at the P < 0.001 level, and mean CV values of <3% in both cases (see Table 4 ). Xe ADC maps obtained from a healthy nonsmoker (group a) and a patient with COPD. The mean ADC over all slices is quoted underneath each dataset. FIGURE 4: Correlation between mean 3 He and 129 Xe ADC glob in healthy nonsmokers (group a), ex-smokers, and patients with COPD, with associated Spearman's correlation coefficient (r) and P value of statistical significance. The dashed line represents a linear fit to the data and error bars represent the standard deviation of repeated scans for each COPD patient.
ICC coefficients and CVs of ADC glob values were comparable to those of FEV 1 and FEV 1 /FVC, and considerably less than those of D LCO and VV%.
Discussion
This work indicates that 129 Xe lung MRI can provide equivalent regional information on lung ventilation and microstructure to 3 He MRI at to-date the most-reported field strength for lung MRI, 1.5T. Specifically, we demonstrated a clear agreement between 129 Xe ventilation and diffusion MRI measurements and 3 He equivalent measurements; these findings substantiate previous work from the Robarts group that was performed at 3T with lower spatial resolution imaging. 3, 15, 16 We also quantified the repeatability of 129 Xe ventilation and diffusion-weighted MRI metrics against 3 He equivalent measurements in COPD patients. 3 He and 129 Xe VV% correlated strongly, with a positive bias towards increased VV% for 3 He. Discrepancies can likely be attributed to differences in image slice thickness, gas polarization, and the fundamental properties of the gases as discussed below. The generally lower VV% of 129 Xe may be explained by the 5-fold lower diffusion coefficient of xenon in air (as confirmed by the mean ADCs of the two gases measured in healthy lungs here), and the resulting slower penetration of partially obstructed airways, although the relatively lower mean SNR of 129 Xe ventilation images may also contribute to this observation. In patients with severe disease, partially obstructed airways may cause an accentuation of this diffusion-related effect, leading to observation of further ventilation abnormalities with 129 Xe when compared with 3 He. We note that a time-dependent diffusive effect of delayed filling of ventilation defects and collateral ventilation has been observed in COPD patients by 3 He MRI, 31 and attributed to lower diffusivity. Furthermore, systematically higher absolute ventilated volumes have been reported for 3 He when compared with 129 Xe at 3T, 15 wherein it was suggested that 3 He has a higher propensity to flow through collateral channels in COPD patients. Nevertheless, this property of 129 Xe could prove useful in the assessment of early (ie, small-scale) structural abnormalities of distal airways and lung parenchyma in a variety of pulmonary diseases, provided that equivalent image SNR and spatial resolution can be achieved as that of 3 He MRI. The lower CV values (and higher ICC coefficients) of 3 He), and the differences in lung inflation level in some cases between 129 Xe and anatomical 1 H images acquired in a separate breath-hold. 28 As mentioned in the Materials and Methods, polarization levels, and thus image SNR, affect the ventilation heterogeneity and therefore images with low SNR (<5) can significantly distort the physiological interpretation of the data. The relatively lower SNR may be explained by the fact that a prototype 129 Xe polarizer (producing 129 Xe polarization 10-15%) was used for most 129 Xe experiments in this work. 12 We have since developed and optimized a clinical-scale polarizer capable of rapidly producing 129 Xe polarized to 40%, which will enable improved 129 Xe image SNR in future studies. 27 Nevertheless, the CV of 129 Xe VV% is severely biased by an outlying subject (CV of Journal of Magnetic Resonance Imaging 25%); the CV in all other COPD patients was 10%. The 129 Xe images from the first scan session in this outlying subject were excluded from analysis because of insufficient SNR. Despite this observation, no other metrics showed abnormally high CV for that patient and no differences in the patient's clinical status were noted.
The high regional heterogeneity of COPD may explain the increased CV of VV% when compared with ADC glob (ADC maps are of lower resolution than ventilation images), although we note that, qualitatively, the prominent areas of ventilation defect were observed repeatedly over scan sessions. Furthermore, the variability of bronchodilator therapy applied on a day-to-day basis will potentially impact VV% more severely than ADC. Nonetheless, both 3 He and 129 Xe VV% CV values calculated from COPD patient data are similar to week-to-week percentage variability in FEV 1 and D LCO , 32 and same-day statistically sound intertimepoint repeatability analysis; hence, the repeatability was only analyzed over all scan sessions. Data regarding day-to-day and week-to-week repeatability is critical for understanding the natural physiological variability in VV% and ADC glob in patients and discriminating this from measurement uncertainty.
In conclusion, the findings reported herein demonstrate that 129 Xe is approaching readiness as a clinically viable alternative to 3 He for quantitative lung ventilation and microstructural MRI studies. For future dissemination and multisite cross-platform clinical trials, the fact that our results agree with many of the trends seen in prior studies that benchmarked 3 He and
129
Xe MRI measurements at 3T is encouraging. Although quantitative measurements of ventilation and ADC will be biased by magnetic susceptibility effects at the two field strengths, we believe that equivalent functional information can be achieved with both gases at both field strengths. In addition, the high repeatability of both 3 He and 129 Xe ADC observed here is perhaps the most convincing evidence to date that 129 Xe ADC imaging has developed into a robust microstructural imaging methodology. Moreover, this report builds upon previous measurements at 3T in terms of improved spatial resolution of 129 Xe imaging, and the realization of 3D DW-MRI with both nuclei 35, 36 is extremely promising for further validation and clinical application in the near future. The preliminary assessment of the repeatability of 129 Xe ventilation and diffusion MRI biomarkers addresses a gap in knowledge that was not considered prior to this work and paves the way for further, more comprehensive multisite repeatability studies.
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